Summary
This unique training is focusing on highly evolving areas of Value Added Medicines business development. The participants will explore the scientific, regulatory, intellectual property and clinical challenges of innovative generic portfolio design.
Who should attend?
Product portfolio planners, Business development, C-level executives, Heads of R&D, Regulatory affairs, Market access, Mergers and Acquisitions managers, Intellectual property, Pricing & reimbursement
Learning Objectives
- The concept of value in the health care environment
- Analyse the market before embarking on an added value strategy
- Create viable business models in different markets
- Is repositioning a high-risk strategy – when could it be suitable for your company?
- How to differentiate a generic product
- Select the right route to drug approval
- What type of products to stay away from because of clinical barriers
- How to protect your investment through IP
Key Topics
- Innovative Generic Business Development
- A concept of value in health care environment
- Market Access for Value Added Medicines
- Drug Repositioning / Repurposing
- Scientific and Technological solutions for Value Added Medicines
- Clinical aspects
- IP and data exclusivity
- Formulation patents: successes and failures
Programme
- All training materials will be provided in digital form
- All delegates will receive digital and LinkedIn certificates
- An in-depth scientific discussion of different mechanisms that could lead to an added value product
- Selecting the right route to drug approval is an essential part of the added value process
- Case studies of Formulation patents – successes and failures
- Recent cases regarding Formulation patents and Swiss “use” patents
- Consequences of market switch from Brand to INN generics
Trainers
Share This Training
